Abstract
Objective: The aim of this study was to evaluate the differences of the in vivo efficacies of Levovist® (SH U 508 A) and Albunex®, air-based contrast agents (CAs) with different shell materials, by direct comparison. Methods: SH U 508 A, 300 mg/ml, and Albunex® were injected intravenously at doses of 0.1 and 0.15 ml/kg, respectively, into the same dogs ( n=6). Contrast enhancement in the left ventricle was evaluated visually and by off-line measurement of brightness. Results: Both CAs yielded good peak contrast, while the duration of contrast enhancement with SH U 508 A was seven times that with Albunex®. With Albunex®, reduction of contrast enhancement at end-systole and in the late phase of diastole during one heartbeat was observed, and a positive correlation was observed between contrast enhancement and heart rate. Contrast enhancement was nearly constant during one heartbeat with SH U 508 A. Conclusion: SH U 508 A yielded consistent and longer contrast enhancement in the left ventricle than Albunex® under the same conditions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
